Digestive and Liver Disease Supplements最新文献_第4页

Hyperimmune immunoglobulins: Manufacturing technologies and safety procedures 超免疫免疫球蛋白:制造技术和安全程序

Digestive and Liver Disease Supplements Pub Date : 2009-12-01 DOI: 10.1016/S1594-5804(09)60038-3

N. Marzo, F. Belda, P. Ristol, M. López, R. Gajardo, J.I. Jorquera

{"title":"Hyperimmune immunoglobulins: Manufacturing technologies and safety procedures","authors":"N. Marzo, F. Belda, P. Ristol, M. López, R. Gajardo, J.I. Jorquera","doi":"10.1016/S1594-5804(09)60038-3","DOIUrl":"10.1016/S1594-5804(09)60038-3","url":null,"abstract":"<div><p>Instituto Grifols has developed two different sterile and ready to use anti-hepatitis B (anti-HB) enriched immunoglobulin concentrates: Niuliva® is a 5% intravenous immunoglobulin solution with 250 IU/ml anti-HB potency, and Gamma anti-hepatitis B Grifols® (Igantibe®in some countries) is a 16% intramuscular immunoglobulin solution with 200 IU/ml anti-HB potency. The production process includes careful plasma donor selection, analysis to discard specific markers of relevant viral infections in the individual donations and plasma pools and, in order to further increase the safety margin, steps aimed at eliminating potential pathogenic agents (e.g., pasteurization). Characterisation studies from both products showed high IgG purity (more than 99%) and an IgG subclass distribution similar to normal plasma. Other potential accompanying proteins (eg: IgA, IgM, albumin, transferrin, etc) were undetectable or very low. Results from additional parameters (identification, total protein, molecular distribution, etc.) meet European Pharmacopoeia's requirements. The stability profile indicates that the products are stable between 2°C and 8°C for two years (Gamma anti-hepatitis B Grifols®) or three years (Niuliva®), maintaining the anti-HB potency.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(09)60038-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81004580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Split and living donor liver transplantation 劈裂肝和活体肝移植

Digestive and Liver Disease Supplements Pub Date : 2009-12-01 DOI: 10.1016/S1594-5804(09)60033-4

J.C. García-Valdecasas

{"title":"Split and living donor liver transplantation","authors":"J.C. García-Valdecasas","doi":"10.1016/S1594-5804(09)60033-4","DOIUrl":"10.1016/S1594-5804(09)60033-4","url":null,"abstract":"<div><p>The split liver transplant allows for the division of a graft in two parts, usually the right side for an adult and the left side for use in a child. To date, many centres have confirmed the efficacy and safety of the procedure. However, the highly demanding surgery and the relatively low activity, associated with the low number of ideal donors, and few adequate recipients, and most of all, the compromised long-term outcome, have resulted in a significant decrease of adult to adult split liver transplantation. The real incidence of morbidity and mortality has been a matter of controversy. While some authors suggest a 15% morbidity rate, others have pointed out a higher incidence reaching up to 70%. Recent data, however, show that at least 38% of all donors had some type of complication: The official European Liver Transplant Registry (ELTR) guarantees that the mortality rate associated to the donor operation is well established in Europe (0.2%, 1997–2007). To date post-transplant survival at one and three years are 92% and 84.8% respectively. To summarize, currently, adult living donor liver transplantation has the same probability of survival at 1 and 5 years when compared to deceased donor liver transplantation.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(09)60033-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82124729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Pool expansion for organ procurement: Older donors for liver transplantation 扩大器官获取池:老年肝移植供体

Digestive and Liver Disease Supplements Pub Date : 2009-12-01 DOI: 10.1016/S1594-5804(09)60034-6

F. Filipponi

引用次数: 0

Liver Transplantation Interdisciplinary Conference (1) 肝移植跨学科会议(1)

Digestive and Liver Disease Supplements Pub Date : 2009-12-01 DOI: 10.1016/S1594-5804(09)00017-5

Vicente Arroyo (Professor of Medicine)

引用次数: 0

New therapeutic approaches for long-term control of chronic hepatitis B 长期控制慢性乙型肝炎的新治疗方法

Digestive and Liver Disease Supplements Pub Date : 2009-11-01 DOI: 10.1016/S1594-5804(09)60025-5

M.R. Brunetto

引用次数: 1

Conclusions 结论

Digestive and Liver Disease Supplements Pub Date : 2009-11-01 DOI: 10.1016/S1594-5804(09)60026-7

M. Colombo

引用次数: 0

Chronic hepatitis B: Do we know everything or is there still something to learn? 慢性乙型肝炎:我们是否知道一切，还是还有一些需要学习?

Digestive and Liver Disease Supplements Pub Date : 2009-11-01 DOI: 10.1016/S1594-5804(09)60024-3

V. Di Marco

引用次数: 1

Treatment options for small intestinal bacterial overgrowth 小肠细菌过度生长的治疗方案

Digestive and Liver Disease Supplements Pub Date : 2009-07-01 DOI: 10.1016/S1594-5804(09)60020-6

M. Gabrielli, L. Sparano, D. Roccarina, G. Vitale, E.C. Lauritano, A. Gasbarrini

{"title":"Treatment options for small intestinal bacterial overgrowth","authors":"M. Gabrielli, L. Sparano, D. Roccarina, G. Vitale, E.C. Lauritano, A. Gasbarrini","doi":"10.1016/S1594-5804(09)60020-6","DOIUrl":"10.1016/S1594-5804(09)60020-6","url":null,"abstract":"<div><p>The best therapeutic approach for patients with small bowel bacterial overgrowth is a combination of the removal of all predisposing conditions and the administration of broad-spectrum antibiotics. In the case of non-modifiable predisposing factors, patients with bacterial overgrowth need a strict follow-up after successful decontamination with antibiotics, in order to promptly assess and treat disease recurrence. Up to now, the choice of antibiotics has been primarily empiric because of the presence of several different bacterial species in the contaminating flora and the impossibility of applying <em>in vitro</em> susceptibility tests. Several systemic and non-absorbable antibiotic agents have been shown to be effective for decontamination of small bowel bacterial overgrowth. The best antibiotic scheme in terms of drug, dosage and duration of therapy remains, however, to be assessed. The non-absorbable agents seem to be associated with better safety and tolerability than systemic drugs. In the present paper, all available therapeutic approaches to small bowel bacterial overgrowth are reviewed.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(09)60020-6","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89326725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Bacterial flora, gas and antibiotics 细菌菌群，气体和抗生素

Digestive and Liver Disease Supplements Pub Date : 2009-07-01 DOI: 10.1016/S1594-5804(09)60021-8

A. Colecchia , D. Festi , E. Scaioli , V. Ruggiero , M. Berardino , P. Portincasa

{"title":"Bacterial flora, gas and antibiotics","authors":"A. Colecchia , D. Festi , E. Scaioli , V. Ruggiero , M. Berardino , P. Portincasa","doi":"10.1016/S1594-5804(09)60021-8","DOIUrl":"10.1016/S1594-5804(09)60021-8","url":null,"abstract":"<div><p>The human gastrointestinal microflora is a complex ecosystem with about 500 different bacterial species. In healthy individuals, the human stomach and the proximal small bowel contain only a few bacterial species, with the terminal ileum considered a transitional zone between the proximal small bowel aerobic microflora and the colonic anaerobic bacteria. The colon hosts a complex and variegate microbiota, including anaerobes (bacteroides, bifidobacteria, lactobacilli and clostridium), and several other species. The enteric microflora is involved in protective, trophic and metabolic functions. The interaction between gut microflora and substrate leads to gas production, while their overproduction can be responsible of the “gas-related syndrome”, a constellation of non-specific gastrointestinal symptoms (bloating, borborygms, flatulence, abdominal distension and discomfort). Any condition leading to the perturbation of the equilibrium between enteric flora and the surrounding system is a predisposing factor for bacterial overgrowth. Proposed antimicrobic treatments, including tetracycline and norfloxacin, amoxicillin-clavulanic acid and <em>S. Boulardii</em>, are still highly empiric. The efficacy of rifaximin, a non-absorbable antibiotic with bactericidal action against anaerobes and aerobes and a low toxicity, has been evaluated in patients with small intestinal bacterial overgrowth and gas-related syndrome, and has a potential therapeutic role in a subgroup of patients.</p></div>","PeriodicalId":100375,"journal":{"name":"Digestive and Liver Disease Supplements","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1594-5804(09)60021-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73067202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Intestinal gas metabolism 肠道气体代谢

Digestive and Liver Disease Supplements Pub Date : 2009-07-01 DOI: 10.1016/S1594-5804(09)60015-2

M. Montalto , M. Di Stefano , A. Gasbarrini , G.R. Corazza

引用次数: 12